Diadema Partners LP Purchases Shares of 101,502 GH Research PLC (NASDAQ:GHRS)

Diadema Partners LP purchased a new stake in GH Research PLC (NASDAQ:GHRS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 101,502 shares of the company’s stock, valued at approximately $711,000. Diadema Partners LP owned approximately 0.20% of GH Research at the end of the most recent reporting period.

Separately, Geode Capital Management LLC raised its stake in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after acquiring an additional 3,092 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Stifel Nicolaus boosted their target price on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, January 27th. Guggenheim assumed coverage on shares of GH Research in a research report on Thursday, March 13th. They issued a “buy” rating and a $32.00 price target on the stock. Royal Bank of Canada began coverage on shares of GH Research in a research report on Friday, March 7th. They set an “outperform” rating and a $31.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on shares of GH Research in a research note on Thursday, February 13th. They set an “overweight” rating and a $14.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $30.86.

GH Research Stock Up 0.8 %

Shares of GH Research stock opened at $9.17 on Tuesday. GH Research PLC has a 12-month low of $6.00 and a 12-month high of $20.50. The company has a 50-day simple moving average of $10.92 and a 200 day simple moving average of $9.61. The stock has a market capitalization of $477.10 million, a P/E ratio of -11.61 and a beta of 0.84.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. On average, equities analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current year.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).